AGIO Stock Slumps 25% – What’s The Novo Connection?

• Novo’s Phase 3 trial evaluating Etavopivat for sickle cell disease showed a reduction in the number of painful vaso-occlusive crises.
• While Agios’ Mitapivat lowered the annual rate of sickle cell pain crises versus placebo, the result was not statistically significant. 
• Truist says Novo’s update could hamper AGIO stock’s ability to rebound to $40.

Shares of Agios Pharmaceuticals (AGIO) tumbled more than 25% on Monday, snapping a five-day winning streak, after Novo Nordisk reported strong topline results from a sickle cell disease treatment trial, raising concerns about increasing competition.

Meanwhile, Truist said that AGIO could face pressure following Novo Nordisk’s headlines.

Novo’s Trial Meets Both Primary Endpoints

Novo’s Phase 3 HIBISCUS trial evaluating Etavopivat for sickle cell disease met both primary endpoints, with the treatment helping reduce the number of painful vaso-occlusive crises and delaying the median time to first crisis by nearly four months compared with placebo.

In contrast, Agios’ Phase 3 RISE UP trial of Mitapivat in sickle cell disease fell short of key goals last November. While Mitapivat reduced the yearly rate of sickle cell pain crises compared to placebo, the difference was not statistically significant. Moreover, patients did not show any improvement in fatigue levels from baseline.

Sickle cell disease is a hereditary condition in which red blood cells become hard and sickle-shaped, making them difficult to move through blood vessels. This can block blood flow, causing pain and organ damage. The disease can lead to complications such as pain crises, anemia, infections, stroke, and long-term organ problems.

The once-daily oral therapy also showed strong improvements in hemoglobin levels, with 48.7% of patients seeing an increase, compared to 7.2% on placebo. Novo Nordisk plans to seek its first regulatory approval in the second half of 2026.

Truist Says Competitive Overhang Could Limit Agios’ Upside

Truist’s Gregory Renza said Novo Nordisk’s positive Phase 3 data could weigh on Agios’ shares. He described the update as a competitive overhang that may limit the stock’s ability to rebound toward $40. AGIO shares traded around $27 at noon on Monday.

Renza believes much of the impact from mixed data is already reflected in Agios’ valuation. He still sees a role for Mitapivat in treating sickle cell disease and expects the company to benefit from its growing presence and credibility in the hematology space. Renza maintained a “Buy” rating with a $39 price target for Agios.

How Did Retail Traders React?

Despite the sharp intraday slide, retail sentiment on AGIO changed to ‘bullish’ from ‘neutral,’ amid ‘high’ message volumes.

One user said AGIO stock is a good “long-term investment.”

Year to date, AGIO shares fell 3.6%.

For updates and corrections, email newsroom[at]stocktwits[dot]com